CN114778839A - CEA electrochemical detection kit based on eATRP signal amplification strategy and detection method - Google Patents
CEA electrochemical detection kit based on eATRP signal amplification strategy and detection method Download PDFInfo
- Publication number
- CN114778839A CN114778839A CN202210359045.2A CN202210359045A CN114778839A CN 114778839 A CN114778839 A CN 114778839A CN 202210359045 A CN202210359045 A CN 202210359045A CN 114778839 A CN114778839 A CN 114778839A
- Authority
- CN
- China
- Prior art keywords
- solution
- electrode
- cea
- eatrp
- apt2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 17
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 17
- 238000000835 electrochemical detection Methods 0.000 title claims abstract description 12
- 238000001514 detection method Methods 0.000 title abstract description 31
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- 101150064015 FAS gene Proteins 0.000 claims abstract description 24
- 101150039095 Lypla1 gene Proteins 0.000 claims abstract description 24
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000010931 gold Substances 0.000 claims abstract description 17
- 229910052737 gold Inorganic materials 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 7
- -1 Apt2 Proteins 0.000 claims abstract description 6
- 229910001486 lithium perchlorate Inorganic materials 0.000 claims abstract description 5
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 25
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000006116 polymerization reaction Methods 0.000 claims description 17
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 11
- 239000012498 ultrapure water Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 229910013684 LiClO 4 Inorganic materials 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000252506 Characiformes Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 claims description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 238000002484 cyclic voltammetry Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003999 initiator Substances 0.000 abstract description 12
- 229920000642 polymer Polymers 0.000 abstract description 11
- 125000003277 amino group Chemical group 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 abstract 2
- 101150019478 APT1 gene Proteins 0.000 abstract 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 abstract 1
- 229910021135 KPF6 Inorganic materials 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- VMGSQCIDWAUGLQ-UHFFFAOYSA-N n',n'-bis[2-(dimethylamino)ethyl]-n,n-dimethylethane-1,2-diamine Chemical compound CN(C)CCN(CCN(C)C)CCN(C)C VMGSQCIDWAUGLQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 77
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 52
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 52
- 229920002873 Polyethylenimine Polymers 0.000 description 25
- XXSPGBOGLXKMDU-UHFFFAOYSA-N 2-bromo-2-methylpropanoic acid Chemical compound CC(C)(Br)C(O)=O XXSPGBOGLXKMDU-UHFFFAOYSA-N 0.000 description 20
- UGZAJZLUKVKCBM-UHFFFAOYSA-N 6-sulfanylhexan-1-ol Chemical compound OCCCCCCS UGZAJZLUKVKCBM-UHFFFAOYSA-N 0.000 description 14
- 238000004365 square wave voltammetry Methods 0.000 description 11
- 230000035484 reaction time Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 6
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 229910017489 Cu I Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011896 sensitive detection Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004502 linear sweep voltammetry Methods 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000027756 respiratory electron transport chain Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012712 reversible addition−fragmentation chain-transfer polymerization Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000006416 CBr Chemical group BrC* 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100495393 Rattus norvegicus Ceacam3 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001746 electroactive polymer Polymers 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000011262 electrochemically active material Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001453 impedance spectrum Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/48—Systems using polarography, i.e. measuring changes in current under a slowly-varying voltage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种基于eATRP信号放大策略的CEA电化学检测试剂盒及检测方法,属于生物分析技术领域。The invention relates to a CEA electrochemical detection kit and a detection method based on an eATRP signal amplification strategy, belonging to the technical field of biological analysis.
背景技术Background technique
随着社会经济的快速发展,人们的生活水平获得了显著的提高,但与此同时,全球癌症患者数量在逐渐增加,严重威胁着人类健康和生命安全。因此,建立一种快速、准确、灵敏检测肿瘤的方法具有重要意义。With the rapid development of social economy, people's living standards have been significantly improved, but at the same time, the number of cancer patients in the world is gradually increasing, which is a serious threat to human health and life safety. Therefore, it is of great significance to establish a rapid, accurate and sensitive method for tumor detection.
肿瘤标志物(Tumor markers,TM)是细胞癌变过程中刺激机体产生的物质,表现为含量异常。检测肿瘤标志物,可以帮助早期诊断,并延长患者生存期。癌胚抗原(CEA)是一种广谱肿瘤标志物,存在于内胚层细胞分化而来的癌症细胞表面,经细胞膜传递后分泌到细胞外,在周围血清、胃液等体液中均能检出CEA成分。该成分在肺癌、乳腺癌、宫颈癌、胃癌等恶性肿瘤中都呈现出较高水平,临床应用广泛。在多种类型癌症的早期诊断、治疗评价、发展、监测及预后等方面有着重要作用。但是疾病早期标志物在体液中含量较低,而且人体环境复杂,直接检测的难度较大,对检测方法的检测限要求高。Tumor markers (TM) are substances that stimulate the body to produce during the process of cell carcinogenesis, and their content is abnormal. Detection of tumor markers can help early diagnosis and prolong patient survival. Carcinoembryonic antigen (CEA) is a broad-spectrum tumor marker that exists on the surface of cancer cells differentiated from endoderm cells. It is secreted to the outside of the cell after passing through the cell membrane. CEA can be detected in peripheral serum, gastric juice and other body fluids. Element. This component shows a high level in lung cancer, breast cancer, cervical cancer, gastric cancer and other malignant tumors, and is widely used in clinical practice. It plays an important role in the early diagnosis, treatment evaluation, development, monitoring and prognosis of various types of cancer. However, the content of early markers of disease in body fluids is relatively low, and the human environment is complex, which makes direct detection difficult and requires high detection limits for detection methods.
目前已经有多种方法被报道用于检测CEA,酶联免疫吸附测定(ELISA)、放射免疫测定(RIA)、化学发光免疫测定(CLIA)、化学发光酶免疫测定(CLEIA)等。生物传感器作为一种典型的多学科交叉和发展的产物。作为一种新兴的检测方法,由于其灵敏度高、操作简单、特异性强等优点受到了广泛关注。其主要由分子识别元件、信号转换元件和信号放大装置三部分组成,分子识别元件通常使用具有特异性结合目标物能力的抗体、酶、DNA等分子,增加传感器的特异性。信号转换元件可以将产生的生物信号转化为可测量的电信号或者荧光信号。传统传感器的目标分子上只能连接一个信号分子,导致传感器的灵敏度难以达到检测需求,为了增加传感器的灵敏度,信号放大装置将产生的信号进一步放大,从而实现对微量标志物的高灵敏检测。Various methods have been reported for the detection of CEA, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), chemiluminescence immunoassay (CLIA), chemiluminescence enzyme immunoassay (CLEIA) and so on. Biosensors are a typical product of multidisciplinary crossover and development. As an emerging detection method, it has received extensive attention due to its high sensitivity, simple operation, and strong specificity. It is mainly composed of three parts: molecular recognition element, signal conversion element and signal amplification device. Molecular recognition element usually uses antibodies, enzymes, DNA and other molecules with specific binding ability to increase the specificity of the sensor. The signal conversion element can convert the generated biological signal into a measurable electrical or fluorescent signal. The target molecule of traditional sensors can only be connected to one signal molecule, which makes it difficult for the sensitivity of the sensor to meet the detection requirements. In order to increase the sensitivity of the sensor, the signal amplification device further amplifies the generated signal, so as to achieve highly sensitive detection of trace markers.
常用的信号放大策略主要包括纳米材料、天然酶以及聚合物链等手段。然而,金属纳米材料昂贵、制备过程复杂,酶的性质不稳定,容易受到外界环境如pH、温度等的影响。聚合物链法能够有效地将单个信号分子接枝到聚合物骨架上,从而显著增加电极上信号分子的负载量,是一种高效、简单而经济的新型信号放大策略。目前已经有多种聚合方法有:原子转移自由基聚合(ATRP)、开环聚合(ROP)、可逆加成-断裂链转移聚合(RAFT)、点击(Click)聚合等。本发明旨在构建一种基于eATRP信号放大策略的电化学检测试剂盒用于高灵敏检测CEA。Commonly used signal amplification strategies mainly include nanomaterials, natural enzymes, and polymer chains. However, metal nanomaterials are expensive, complicated in preparation process, and unstable in properties of enzymes, which are easily affected by external environments such as pH and temperature. The polymer chain method can effectively graft a single signal molecule onto the polymer backbone, thereby significantly increasing the loading of the signal molecule on the electrode, which is an efficient, simple and economical new signal amplification strategy. At present, there are many polymerization methods: atom transfer radical polymerization (ATRP), ring-opening polymerization (ROP), reversible addition-fragmentation chain transfer polymerization (RAFT), click polymerization, etc. The present invention aims to construct an electrochemical detection kit based on the eATRP signal amplification strategy for highly sensitive detection of CEA.
发明内容SUMMARY OF THE INVENTION
针对现有技术的不足,本发明的目的是提供一种基于eATRP信号放大策略的CEA电化学检测试剂盒及检测方法,克服了传统ATRP反应中催化剂对空气敏感的缺点,且灵敏度高、特异性好、操作简单,在人血清检测中具有良好的适用性。In view of the deficiencies of the prior art, the purpose of the present invention is to provide a CEA electrochemical detection kit and detection method based on the eATRP signal amplification strategy, which overcomes the shortcoming that the catalyst is sensitive to air in the traditional ATRP reaction, and has high sensitivity and specificity. It is good, simple to operate, and has good applicability in the detection of human serum.
为了实现上述目的,本发明的技术方案之一是:In order to achieve the above object, one of the technical solutions of the present invention is:
基于eATRP信号放大策略的CEA电化学检测试剂盒,包括以下原料:Apt1、Apt2、MCH、PEI、BMP、Me6TREN、CuBr2、KPF6、FMMA、LiClO4、EDC、NHS、DMSO、H2SO4、无水乙醇、PBS缓冲液、超纯水。其中,CEA electrochemical detection kit based on eATRP signal amplification strategy, including the following raw materials: Apt1, Apt2, MCH, PEI, BMP, Me 6 TREN, CuBr 2 , KPF 6 , FMMA, LiClO 4 , EDC, NHS, DMSO, H 2 SO 4 , absolute ethanol, PBS buffer, ultrapure water. in,
Apt1序列:5’-SH-(CH2)6-ATACCAGCTTATTCAATT-3’Apt1 sequence: 5'-SH-(CH 2 ) 6 -ATACCAGCTTATTCAATT-3'
Apt2序列:5’-AGGGGGTGAAGGGATACCC-3’。Apt2 sequence: 5'-AGGGGGTGAAGGGATACCC-3'.
进一步,使用时,将部分原料配制为溶液,Apt1溶液浓度为1μM,Apt2溶液浓度为100μM,EDC溶液浓度为100μM,NHS溶液浓度为100μM,MCH溶液浓度为2mM,PEI溶液浓度为2mg/mL,BMP溶液浓度为2mM,KPF6溶液浓度为0.1M,FMMA溶液浓度为10mM,CuBr2/Me6TREN溶液中CuBr2和Me6TREN的浓度均为10mM,LiClO4溶液浓度为1.0M。Further, when using, some raw materials are prepared into solutions, the concentration of Apt1 solution is 1 μM, the concentration of Apt2 solution is 100 μM, the concentration of EDC solution is 100 μM, the concentration of NHS solution is 100 μM, the concentration of MCH solution is 2mM, and the concentration of PEI solution is 2 mg/mL, The concentration of BMP solution is 2 mM, the concentration of KPF 6 solution is 0.1 M, the concentration of FMMA solution is 10 mM, the concentration of CuBr 2 and Me 6 TREN in CuBr 2 /Me 6 TREN solution is both 10 mM, and the concentration of LiClO 4 solution is 1.0 M.
本发明的技术方案之一是:一种检测CEA的方法,包括以下步骤:One of the technical solutions of the present invention is: a method for detecting CEA, comprising the following steps:
(1)电极修饰(1) Electrode modification
①将Apt1溶液滴加到金电极上,反应,洗涤,吹干;①Drop the Apt1 solution onto the gold electrode, react, wash, and dry;
②将步骤①的电极浸泡在MCH溶液中,反应,洗涤,吹干;② Soak the electrode of
③将待检测样品滴加至步骤②的电极表面,反应,洗涤,吹干;③ drop the sample to be detected on the electrode surface of
④将Apt2-PEI溶液滴加到步骤③的电极上,反应,洗涤,吹干;④ Add the Apt2-PEI solution dropwise to the electrode in step ③, react, wash, and blow dry;
⑤将BMP溶液滴加到步骤④的电极表面,反应,洗涤,吹干;⑤ Add the BMP solution dropwise to the electrode surface of step ④, react, wash, and blow dry;
⑥将步骤⑤的电极浸泡在eATRP反应溶液中,在恒定电位下,用i-t曲线电化学聚合,随后用LSV方法处理电极,除去表面杂质;⑥ Immerse the electrode in
(2)电化学测定(2) Electrochemical determination
将修饰后的电极浸入LiClO4溶液中,用SWV方法进行电化学检测,根据电信号大小分析CEA含量。The modified electrode was immersed in LiClO4 solution, electrochemical detection was performed by SWV method, and the CEA content was analyzed according to the magnitude of the electrical signal.
进一步,金电极先进行预处理,预处理方法为:用0.3μm和0.05μm氧化铝粉分别对金电极表面进行抛光,然后,依次用超纯水、无水乙醇和超纯水超声清洗电极,将清洗过的电极在新配制的水虎鱼酸溶液中浸泡15min,并重复上述清洗步骤,清洗结束后取出,在0.5M H2SO4溶液中用循环伏安法处理电极,电位范围设定为-0.3~1.5V,扫描速率为0.1V/s,重复扫描直至得到重合的CV图,最后用超纯水清洗电极,用氮气吹干。Further, the gold electrode is pretreated first. The pretreatment method is as follows: polishing the surface of the gold electrode with 0.3 μm and 0.05 μm alumina powder respectively, and then ultrasonically cleaning the electrode with ultrapure water, anhydrous ethanol and ultrapure water in sequence. Soak the cleaned electrode in the freshly prepared piranha acid solution for 15min, and repeat the above cleaning steps, take it out after cleaning, and treat the electrode with cyclic voltammetry in 0.5MH2SO4 solution, and the potential range is set to -0.3~1.5V, the scan rate is 0.1V/s, and the scanning is repeated until the overlapping CV diagrams are obtained. Finally, the electrodes are washed with ultrapure water and dried with nitrogen.
进一步,步骤①的反应温度为37℃,时间为2h;步骤②的反应温度为37℃,时间为0.5h;步骤③的反应温度为37℃,时间为1h;步骤④的反应温度为37℃,时间为1h;步骤⑤的反应温度为37℃,时间为25min;步骤⑥的聚合温度为室温,时间为40min;步骤(2)的SWV的扫描范围:0~0.8V,扫描速率:1.0V/s,电位增量:4mV。Further, the reaction temperature of
进一步,Apt2-PEI溶液的制备方法为:Further, the preparation method of Apt2-PEI solution is:
将Apt2溶液、EDC溶液和NHS溶液等体积混合,然后加入到PBS缓冲液中,振荡活化,得到已活化的Apt2溶液;然后加入等体积的PEI溶液混合,振荡反应,得到Apt2-PEI溶液。Mix equal volumes of Apt2 solution, EDC solution and NHS solution, then add to PBS buffer, shake and activate to obtain activated Apt2 solution; then add equal volume of PEI solution to mix, shake and react to obtain Apt2-PEI solution.
进一步,eATRP反应溶液的制备方法为:Further, the preparation method of eATRP reaction solution is:
①将CuBr2和Me6TREN溶解在DMSO中,制备成CuBr2和Me6TREN浓度均为10mM的CuBr2/Me6TREN溶液;① Dissolve CuBr 2 and Me 6 TREN in DMSO to prepare a CuBr 2 /Me 6 TREN solution with both CuBr 2 and Me 6 TREN concentrations of 10 mM;
②将1.8mL DMSO、0.1mL CuBr2/Me6TREN溶液、0.1mL FMMA溶液和8.0mL KPF6溶液混合,制得eATRP反应溶液。② Mix 1.8 mL of DMSO, 0.1 mL of CuBr 2 /Me 6 TREN solution, 0.1 mL of FMMA solution and 8.0 mL of KPF 6 solution to prepare an eATRP reaction solution.
本发明的技术方案之一是:一种上述试剂盒在检测CEA中的应用。One of the technical solutions of the present invention is: an application of the above-mentioned kit in detecting CEA.
本发明修饰电极的制备方法和检测方法原理如图1所示。The principle of the preparation method and detection method of the modified electrode of the present invention is shown in FIG. 1 .
首先将一端修饰有巯基的CEA适配体1(Apt1)通过“Au-S”共价键自组装到金电极表面,用6-巯基己醇(MCH)封闭金电极未结合的位点。然后,通过适配体与抗原的特异性识别,依次将CEA、Apt2-PEI连接到金电极上。PEI上大量的氨基通过酰胺键与引发剂2-溴-2-甲基丙酸(BMP)连接,从而引入大量eATRP引发位点。接着将电极浸入eATRP反应溶液中,在电化学方法i-t下进行电催化聚合,信号单元二茂铁甲醇异丁烯酸脂(FMMA)被聚合到电极上;将聚合后的电极立即用线性扫描伏安法(LSV)处理,除去电极表面吸附的杂质。最后将制备完成的电极置于高氯酸锂电解液中,应用方波伏安法(SWV)测试检测的性能。First, the CEA aptamer 1 (Apt1) with one end modified with a thiol group was self-assembled onto the surface of the gold electrode through the "Au-S" covalent bond, and the unbound site of the gold electrode was blocked with 6-mercaptohexanol (MCH). Then, through the specific recognition of the aptamer and the antigen, CEA and Apt2-PEI were sequentially connected to the gold electrode. A large number of amino groups on PEI are linked to the initiator 2-bromo-2-methylpropionic acid (BMP) through an amide bond, thereby introducing a large number of eATRP initiation sites. Then, the electrode was immersed in the eATRP reaction solution, electrocatalytic polymerization was carried out under the electrochemical method i-t, and the signal unit ferrocene methanol methacrylate (FMMA) was polymerized on the electrode; the polymerized electrode was immediately subjected to linear scanning voltammetry. (LSV) treatment to remove impurities adsorbed on the electrode surface. Finally, the prepared electrode was placed in a lithium perchlorate electrolyte, and the performance was tested by square wave voltammetry (SWV).
电化学介导的ATRP过程以BMP为引发剂、CuBr2为催化剂、Me6TREN为配体,反应涉及低价态的CuI活化剂与高价态的CuII失活剂之间的可逆转化。CuIIBr/Me6TREN+在负电位电压下还原为CuIBr/Me6TREN,CuIBr/Me6TREN进一步解离为CuI/Me6TREN+和Br-。以CuI/Me6TREN+为激活剂,与引发剂上的活性位点C-Br反应生成初始自由基(R·)和CuIIBr/Me6TREN+钝化剂。然后R·与FMMA反应生成链自由基R-FMMA。R-FMMA与CuIIBr/Me6TREN+反应生成目标产物R-FMMA-Br。钝化剂通过与链自由基反应或通过电化学还原转化为CuI/Me6TREN+,可再次启动新一轮反应。整个催化系统通过氧化还原反应在活物种和休眠物种之间建立可逆的动态平衡。随着信号单体FMMA不断加入到链自由基中,目标分子被大量接枝电极表面,可实现对CEA的高灵敏检测。The electrochemically mediated ATRP process uses BMP as the initiator, CuBr 2 as the catalyst, and Me 6 TREN as the ligand, and the reaction involves a reversible transformation between a low-valence Cu I activator and a high-valence Cu II inactivator. Cu II Br/Me 6 TREN + was reduced to Cu I Br/Me 6 TREN under negative potential voltage, and Cu I Br/Me 6 TREN was further dissociated into Cu I /Me 6 TREN + and Br − . Using Cu I /Me 6 TREN + as an activator, it reacted with the active site C-Br on the initiator to generate initial radicals (R·) and Cu II Br/Me 6 TREN + passivation agent. Then R· reacts with FMMA to generate chain radical R-FMMA. R-FMMA reacts with Cu II Br/Me 6 TREN + to generate the target product R-FMMA-Br. The passivating agent can be converted into Cu I /Me 6 TREN + by reacting with chain radicals or by electrochemical reduction, which can start a new round of reactions again. The entire catalytic system establishes a reversible dynamic equilibrium between active and dormant species through redox reactions. With the continuous addition of the signal monomer FMMA into the chain free radicals, the target molecules are grafted on the electrode surface in large quantities, which can realize the highly sensitive detection of CEA.
本发明的有益效果:Beneficial effects of the present invention:
1、本发明利用大分子聚合物PEI对信号进行放大,避免了使用纳米材料所需的复杂合成过程和使用生物酶时易受外界环境、温度等因素的影响,使得在放大信号的同时,不影响检测的效率和稳定性。1. The present invention uses the macromolecular polymer PEI to amplify the signal, avoiding the complex synthesis process required for the use of nanomaterials and the use of biological enzymes that are easily affected by factors such as external environment, temperature, etc. affect the efficiency and stability of detection.
2、本发明采用电介导的原子转移自由基聚合(eATRP)策略,在传统ATRP可用单体范围广、聚合物结构有序等优势的基础上,可以通过调节电位来调控聚合反应的进程,并且减少金属催化剂的使用,更加有效、环保。2. The present invention adopts an electrically mediated atom transfer radical polymerization (eATRP) strategy. Based on the advantages of traditional ATRP, such as a wide range of available monomers and an ordered polymer structure, the process of the polymerization reaction can be regulated by adjusting the potential. And the use of metal catalysts is reduced, which is more effective and environmentally friendly.
3、本发明以二茂铁甲醇异丁烯酸脂(FMMA)为电化学信号单元,采用eATRP作为信号放大策略,与大分子聚合物PEI实现级联信号放大。Apt1以金-硫键自组装到金电极表面,通过适配体-抗原的特异性识别逐步形成Apt1-CEA-Apt2的三明治夹心结构。PEI预先通过酰胺键与Apt2连接,PEI上的氨基为eATRP引发剂BMP的连接提供大量活性位点。在eATRP反应溶液中,引发剂BMP上的溴基在电极表面诱导eATRP反应发生,大量的电化学活性物质FMMA被接枝到电极上。最后,利用方波伏安法(SWV)检测电流响应值,从而实现对CEA的高灵敏检测。实验结果表明,在10-3~102ng·mL-1范围内,电流信号强度与CEA浓度之间呈现良好的线性关系,得到的线性回归方程为:I=1.1165lg CCEA+4.8054(R2=0.998),其中,I表示电流强度(μA),CCEA为CEA浓度(ng·mL-1),检测限为:70.17fg·mL-1(S/N=3)。实验结果表明,本发明具有良好的稳定性和重现性,并且本发明在实际样品检测中表现出了优越的检测性能,有望成为临床检测CEA的新方法。3. The present invention uses ferrocene methanol methacrylate (FMMA) as the electrochemical signal unit, adopts eATRP as the signal amplification strategy, and realizes cascade signal amplification with the macromolecular polymer PEI. Apt1 self-assembles onto the surface of the gold electrode through gold-sulfur bonds, and gradually forms a sandwich structure of Apt1-CEA-Apt2 through the specific recognition of aptamer-antigen. PEI was previously linked to Apt2 through an amide bond, and the amino group on PEI provided a large number of active sites for the attachment of the eATRP initiator BMP. In the eATRP reaction solution, the bromine group on the initiator BMP induced the eATRP reaction on the electrode surface, and a large amount of electrochemically active material FMMA was grafted onto the electrode. Finally, square wave voltammetry (SWV) is used to detect the current response value, thereby realizing highly sensitive detection of CEA. The experimental results show that in the range of 10 -3 to 10 2 ng·mL -1 , there is a good linear relationship between the current signal intensity and the CEA concentration. The linear regression equation obtained is: I=1.1165lg C CEA +4.8054(R 2 =0.998), where I represents the current intensity (μA), C CEA is the CEA concentration (ng·mL -1 ), and the detection limit is: 70.17 fg·mL -1 (S/N=3). The experimental results show that the present invention has good stability and reproducibility, and the present invention exhibits excellent detection performance in actual sample detection, and is expected to become a new method for clinical detection of CEA.
附图说明Description of drawings
图1A为本发明修饰电极的制备方法图,图1B为eATRP原理示意图。FIG. 1A is a schematic diagram of the preparation method of the modified electrode of the present invention, and FIG. 1B is a schematic diagram of the principle of eATRP.
图2A为不同修饰条件下电极的SWV信号图;图2B为不同扫描速率的CV曲线;图2C为每个步骤修饰后的电极的EIS阻抗曲线;图2D为每个步骤修饰后的电极的CV曲线。Figure 2A is the SWV signal diagram of the electrode under different modification conditions; Figure 2B is the CV curve of the different scan rate; Figure 2C is the EIS impedance curve of the electrode modified in each step; Figure 2D is the CV of the modified electrode in each step curve.
图3为电极表面修饰eATRP前后的原子力显微镜照片。Figure 3 is the atomic force microscope pictures of the electrode surface before and after eATRP modification.
图4为不同修饰状态电极表面的接触角照片。Figure 4 shows the contact angle photographs of the electrode surfaces in different modified states.
图5A为BMP反应时间优化;B为eATRP反应时间优化。Figure 5A shows the optimization of the BMP reaction time; B shows the optimization of the eATRP reaction time.
图6A为不同浓度CEA的SWV响应信号;B为CEA浓度与电流强度之间的线性关系图。Figure 6A is the SWV response signal of different concentrations of CEA; B is the linear relationship between the concentration of CEA and the current intensity.
图7A为试剂盒对10ng·mL-1CEA、CY、BSA、CTnI和100mU·mL-1ALP的选择性;B为不同浓度CEA分别在人血清和PBS缓冲液中的信号强度。Figure 7A shows the selectivity of the kit to 10 ng·mL -1 CEA, CY, BSA, CTnI and 100 mU·mL -1 ALP; B is the signal intensity of different concentrations of CEA in human serum and PBS buffer, respectively.
具体实施方式Detailed ways
以下结合实施例对本发明的具体实施方式作进一步详细说明。The specific embodiments of the present invention will be further described in detail below with reference to the examples.
癌胚抗原(CEA)和所有合成的寡核苷酸,包括CEA1(Apt1:5’-SH-(CH2)6-ATACCAGCTTATTCAATT-3’,SEQ ID NO.1)和CEA2(Apt2:5’-AGGGGGTGAAGGGATACCC-3’,SEQID NO.2)均由生工生物工程(上海)股份有限公司合成。Carcinoembryonic antigen (CEA) and all synthetic oligonucleotides, including CEA1 (Apt1:5'-SH-( CH2 )6-ATACCAGCTTATTCAATT-3', SEQ ID NO. 1) and CEA2 (Apt2:5'- AGGGGGTGAAGGGATACCC-3', SEQ ID NO. 2) were synthesized by Sangon Bioengineering (Shanghai) Co., Ltd.
实施例1:试剂盒Example 1: Kit
基于eATRP信号放大策略的CEA电化学检测试剂盒,包括以下原料:Apt1、Apt2、6-巯基-1-己醇(MCH)、聚乙烯亚胺(PEI)、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)、N-羟基琥珀酰亚胺(NHS)、2-溴-2-甲基丙酸(BMP)、三(2-二甲氨基乙基)胺(Me6TREN)、CuBr2、六氟磷酸钾(KPF6)、二茂铁甲醇异丁烯酸酯(FMMA)、LiClO4、二甲基亚砜(DMSO)、H2SO4、无水乙醇、PBS缓冲液、超纯水。CEA electrochemical detection kit based on eATRP signal amplification strategy, including the following raw materials: Apt1, Apt2, 6-mercapto-1-hexanol (MCH), polyethyleneimine (PEI), 1-(3-dimethylaminopropyl) yl)-3-ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), 2-bromo-2-methylpropionic acid (BMP), tris(2-dimethylamino) Ethyl)amine (Me 6 TREN), CuBr 2 , potassium hexafluorophosphate (KPF 6 ), ferrocene methanol methacrylate (FMMA), LiClO 4 , dimethyl sulfoxide (DMSO), H 2 SO 4 , Absolute ethanol, PBS buffer, ultrapure water.
将部分原料配制为溶液,Apt1溶液浓度为1μM,Apt2溶液浓度为100μM,EDC溶液浓度为100μM,NHS溶液浓度为100μM,MCH溶液浓度为2mM,PEI溶液浓度为2mg/mL,BMP溶液浓度为2mM,KPF6溶液浓度为0.1M,FMMA溶液浓度为10mM,CuBr2/Me6TREN溶液中CuBr2和Me6TREN的浓度均为10mM,LiClO4溶液浓度为1.0M。Part of the raw materials were prepared into solutions, the concentration of Apt1 solution was 1 μM, the concentration of Apt2 solution was 100 μM, the concentration of EDC solution was 100 μM, the concentration of NHS solution was 100 μM, the concentration of MCH solution was 2 mM, the concentration of PEI solution was 2 mg/mL, and the concentration of BMP solution was 2 mM. , the concentration of KPF 6 solution is 0.1M, the concentration of FMMA solution is 10mM, the concentration of CuBr 2 and Me 6 TREN in CuBr 2 /Me 6 TREN solution is both 10mM, and the concentration of LiClO 4 solution is 1.0M.
实施例2:试剂盒的构建Example 2: Construction of the kit
(1)电极预处理(1) Electrode pretreatment
用0.3μm和0.05μm氧化铝粉分别对金电极表面进行抛光。然后,依次用超纯水、无水乙醇和超纯水超声清洗电极。将清洗过的电极在新配制的水虎鱼酸溶液中浸泡15min,并重复上述清洗步骤。清洗结束后立即取出,在0.5M H2SO4溶液中用循环伏安法处理电极,电位范围设定为-0.3~1.5V,扫描速率为0.1V/s,重复扫描直至得到重合的CV图。最后用超纯水清洗电极,氮气吹干。水虎鱼酸溶液的制备方法为:98%H2SO4和H2O2以体积比3:1的比例混合;The surface of the gold electrode was polished with 0.3 μm and 0.05 μm alumina powder, respectively. Then, the electrodes were ultrasonically cleaned with ultrapure water, absolute ethanol and ultrapure water in sequence. Soak the cleaned electrode in the freshly prepared piranha acid solution for 15 min, and repeat the above cleaning steps. Immediately after cleaning, the electrodes were taken out and treated with cyclic voltammetry in a 0.5MH 2 SO 4 solution. The potential range was set to -0.3 to 1.5 V, and the scan rate was 0.1 V/s. The scan was repeated until overlapping CV maps were obtained. Finally, the electrode was rinsed with ultrapure water and dried with nitrogen. The preparation method of piranha acid solution is as follows: 98% H 2 SO 4 and H 2 O 2 are mixed in a volume ratio of 3:1;
(2)修饰电极(2) Modified electrode
①将10μL Apt1溶液(1μM)滴加到电极上,在37℃条件下反应2h,洗涤,吹干。① Add 10 μL of Apt1 solution (1 μM) dropwise to the electrode, react at 37°C for 2 h, wash and dry.
②将步骤①的电极浸泡在300μL MCH溶液(2mM)中,在37℃条件下反应0.5h,洗涤,吹干。② Soak the electrode of
③将10μL待检测溶液(含CEA)滴加至步骤②的电极上,在37℃条件下反应1h,洗涤,吹干。③ Add 10 μL of the solution to be detected (containing CEA) dropwise to the electrode in
④将10μL配制好的Apt2-PEI溶液(1μM)滴加到步骤③的电极上,在37℃条件下反应1h,洗涤,吹干。④ Add 10 μL of the prepared Apt2-PEI solution (1 μM) dropwise to the electrode in step ③, react at 37° C. for 1 h, wash and dry.
⑤将10μL BMP溶液(2mM)滴加到步骤④的电极上,在37℃条件下反应25min,洗涤,吹干。⑤ Add 10 μL of BMP solution (2 mM) dropwise to the electrode in step ④, react at 37° C. for 25 min, wash and dry.
⑥将步骤⑤的电极浸泡在新配制的eATRP反应溶液(10mL)中,在恒定电位下,用i-t曲线(恒定电位:-0.5V;静置时间:3s;采样间隔:0.1s)电化学聚合40min(常温)。随后立即用线性扫描伏安法(LSV)(起始电位:0V;终止电位:0.2V;扫描速率:1V/s)处理电极,除去表面杂质。⑥ Immerse the electrode of
(3)电化学测定(3) Electrochemical determination
将修饰后的电极浸入1.0M LiClO4溶液(10mL)中,用SWV(扫描范围:0~0.8V,扫描速率:1.0V/s,电位增量:4mV)方法进行电化学检测,根据电信号大小分析CEA含量。The modified electrode was immersed in 1.0 M LiClO 4 solution (10 mL), and electrochemical detection was carried out by SWV (scanning range: 0-0.8 V, scanning rate: 1.0 V/s, potential increment: 4 mV), according to the electrical signal Size analysis of CEA content.
Apt2-PEI溶液的制备方法为:The preparation method of Apt2-PEI solution is:
取10μL Apt2溶液(100μM)与等体积的EDC溶液(100μM)和NHS溶液(100μM)混合,然后加入到470μL PBS缓冲液中,放置于37℃恒温摇床中活化2h,得0.5mL已活化的Apt2溶液(2μM);然后加入等体积的PEI溶液(2mg/mL)混合,放置于37℃恒温摇床中反应1h,得到Apt2-PEI溶液(1μM)。
eATRP反应溶液的制备方法为:The preparation method of eATRP reaction solution is:
①将CuBr2和Me6TREN溶解在DMSO中,制备成CuBr2和Me6TREN浓度均为10mM的CuBr2/Me6TREN溶液;① Dissolve CuBr 2 and Me 6 TREN in DMSO to prepare a CuBr 2 /Me 6 TREN solution with both CuBr 2 and Me 6 TREN concentrations of 10 mM;
②将1.8mL DMSO、0.1mL CuBr2/Me6TREN溶液、0.1mL FMMA溶液(10mM)和8.0mLKPF6溶液(0.1M)混合,制得eATRP反应溶液。② Mix 1.8 mL of DMSO, 0.1 mL of CuBr 2 /Me 6 TREN solution, 0.1 mL of FMMA solution (10 mM) and 8.0 mL of KPF 6 solution (0.1 M) to prepare an eATRP reaction solution.
实施例3:可行性验证Example 3: Feasibility Verification
为了评价本发明检测CEA的可行性,采用SWV(1.0M LiClO4,电位范围为0~0.8V)测量一系列修饰电极的氧化还原电流信号,并进行比较。结果如图2A所示,图中的b~e曲线反映了在电极构建过程中不添加Apt1、CEA、Apt2、BMP时,在二茂铁的电位范围内没有明显的氧化电流。这是因为eATRP的引发剂没有被接枝到电极上,导致电催化聚合不会发生。曲线f反映了不添加CuBr2/Me6TREN时,没有明显的氧化电流,说明没有催化剂和配体时eATRP反应不会发生。同样,曲线g表明缺少电活性探针(FMMA)也不会出现明显的信号峰。当上述所有成分被连续修饰到电极表面时,可以检测到明显的电化学信号(曲线a)。这些实验证实了该策略用于CEA检测是可行的。In order to evaluate the feasibility of the present invention to detect CEA, SWV (1.0M LiClO 4 , potential range of 0-0.8V) was used to measure the redox current signals of a series of modified electrodes and compared. The results are shown in Figure 2A. The curves b–e in the figure reflect that there is no obvious oxidation current in the potential range of ferrocene when Apt1, CEA, Apt2, and BMP are not added during the electrode construction. This is because the initiator of eATRP is not grafted onto the electrode, resulting in the electrocatalytic polymerization not taking place. Curve f reflects that there is no obvious oxidation current when CuBr 2 /Me 6 TREN is not added, indicating that the eATRP reaction does not occur without catalyst and ligand. Likewise, curve g shows that in the absence of the electroactive probe (FMMA) there is no distinct signal peak. When all of the above components were continuously modified to the electrode surface, a distinct electrochemical signal could be detected (curve a). These experiments confirmed the feasibility of this strategy for CEA detection.
实施例4:表征Example 4: Characterization
在1.0M KNO3溶液中用CV对新制备的电极用不同扫描速率进行表征,扫描速率为0.01至1.0V/s,电位为0至0.6V。如图2B所示,氧化还原电流与扫描速率呈良好的线性关系,说明电活性聚合物是通过共价键固定到电极上的,而不是依赖扩散的连接。The freshly prepared electrodes were characterized by CV in 1.0 M KNO3 solution with different scan rates ranging from 0.01 to 1.0 V/s and potentials from 0 to 0.6 V. As shown in Figure 2B, the redox current has a good linear relationship with the scan rate, indicating that the electroactive polymer is immobilized to the electrode through covalent bonds rather than diffusion-dependent connections.
EIS能够对电极构建过程中电极表面的改性情况进行表征,在含有0.1M KNO3的5mM[Fe(CN)6]3-/4-电解质溶液中,逐步收集同一电极在连续制备过程中的EIS谱图。在Nyquist图中,半圆的直径表示电荷转移电阻(Rct),是电子在电极表面转移时受到的阻碍。从图2C中可以看出,在阻抗谱中裸金电极(曲线a)的Rct只有281Ω,说明电极表面是干净的,电子可以在电极与溶液界面之间快速转移。Apt1通过“Au-S”固定到电极上后,由于磷酸化位点的Apt1与[Fe(CN)6]3-/4-之间的静电排斥作用,Rct逐渐增大(~954Ω,曲线b)。随后,电极表面多余的结合位点被MCH占据,导致Rct(~1551Ω,曲线c)进一步增大。接下来,CEA与Apt1识别,在电极表面形成蛋白质层,阻碍了电子转移的效率,导致Rct(~2596Ω,曲线d)增加。当Apt2-PEI上被连接到电极上后,Rct(~231Ω,曲线e)显著减少,这是由于PEI上的大量氨基促进电子转移效率造成的。引发剂BMP固定到电极上,Rct(~406Ω,曲线f)再次增大。最后,eATRP后的Rct(~9692Ω,曲线g)显著增加,这是因为大量FMMA被接枝到电极表面,造成空间位阻急剧增加。结果表明,本发明的构建过程是有效的。EIS can characterize the modification of the electrode surface during the electrode construction. In 5mM [Fe(CN) 6 ] 3-/4- electrolyte solution containing 0.1M KNO 3 EIS spectrum. In the Nyquist diagram, the diameter of the semi-circle represents the charge transfer resistance (Rct), which is the resistance to electron transfer across the electrode surface. It can be seen from Figure 2C that the Rct of the bare gold electrode (curve a) in the impedance spectrum is only 281Ω, indicating that the electrode surface is clean and electrons can be rapidly transferred between the electrode and the solution interface. After Apt1 was immobilized on the electrode via "Au-S", Rct gradually increased due to the electrostatic repulsion between Apt1 at the phosphorylation site and [Fe(CN) 6 ] 3-/4- (~954Ω, curve b ). Subsequently, excess binding sites on the electrode surface were occupied by MCH, resulting in a further increase in Rct (∼1551 Ω, curve c). Next, CEA recognizes Apt1 and forms a protein layer on the electrode surface that hinders the efficiency of electron transfer, resulting in an increase in Rct (∼2596 Ω, curve d). When Apt2-PEI was attached to the electrode, Rct (~231 Ω, curve e) was significantly reduced, which was due to the large number of amino groups on PEI promoting electron transfer efficiency. The initiator BMP is immobilized on the electrode and Rct (~406Ω, curve f) increases again. Finally, the Rct (~9692 Ω, curve g) increases significantly after eATRP, which is due to the dramatic increase in steric hindrance due to the large amount of FMMA being grafted to the electrode surface. The results show that the construction process of the present invention is effective.
用CV评价了不同修饰步骤时电极表面的特性。如图2D所示,随着Apt1、MCH、CEA逐步被修饰到电极上,电极表面的峰值电流逐渐减小(55.4~34.7μA,曲线a~d)。当Apt2-PEI附着在电极表面后,峰值电流显著提高(57.7μA,曲线e)。然后,将引发剂修饰到电极上,峰值电流进一步下降(56.2μA,曲线f)。最后,聚合反应将大量FMMA接枝到电极上,峰值电流显著降低(32.3μA,曲线g),CV结果与EIS趋势一致,表明该电极构建成功。The properties of the electrode surface at different modification steps were evaluated by CV. As shown in Figure 2D, as Apt1, MCH, and CEA were gradually modified onto the electrode, the peak current on the electrode surface gradually decreased (55.4-34.7 μA, curves a-d). When Apt2-PEI was attached to the electrode surface, the peak current was significantly increased (57.7 μA, curve e). Then, the initiator was modified onto the electrode, and the peak current decreased further (56.2 μA, curve f). Finally, the polymerization reaction grafted a large amount of FMMA onto the electrode, the peak current was significantly reduced (32.3 μA, curve g), and the CV results were consistent with the EIS trend, indicating that the electrode was successfully constructed.
通过原子力显微镜(AFM)和水接触角(WCA)对电极表面进行了表征。由图3A可知,Apt1/MCH/CEA/Apt2-PEI/BMP修饰金电极的高度为17.9nm。发生eATRP后,由于聚合物在金电极上形成,金电极高度增长为34.0nm(图3B)。这一结果说明聚合物能够在电极上形成,FMMA被成功接枝到电极表面。The electrode surfaces were characterized by atomic force microscopy (AFM) and water contact angle (WCA). It can be seen from Figure 3A that the height of the Apt1/MCH/CEA/Apt2-PEI/BMP modified gold electrode is 17.9 nm. After eATRP occurred, the gold electrode height grew to 34.0 nm due to polymer formation on the gold electrode (Fig. 3B). This result indicated that the polymer could be formed on the electrode, and FMMA was successfully grafted to the electrode surface.
由于在电极表面修饰材料后的亲水性会发生改变,WCA可以用来研究修饰后金电极的亲水性,图4中显示了不同步骤修饰步骤WCA的变化。从图4A中可以看出,由于金电极是疏水的,裸电极的WCA是95.3°。当Apt1被固定在金电极上时,WCA下降到92.3°(图4B),这是由Apt1上的亲水性基团引起的。用MCH封闭表面未结合位点后,WCA变化不大,仅下降到91.2°(图4C),这是因为MCH上既有疏水性基团又有亲水性基团导致的。由于蛋白质中存在亲水的氨基和羧基,当CEA与Apt1特异性识别后,WCA降低到86.8°(图4D)。同样的,由于PEI上存在大量氨基,Apt2-PEI连接到电极上后,WCA显著减小到76.5°(图4E)。BMP通过酰胺键连接到电极上后,由于酰胺键和卤素的作用,WCA减小到72.6°(图4F)。最后,带有FMMA的聚合物链接枝到电极上,由于聚合物中含有亲水性的甲基丙烯酸酯,电极的接触角下降到71.8°(图4G)。以上结果证明本发明用于检测CEA是可行的。Since the hydrophilicity of the electrode surface will change after the material is modified, WCA can be used to study the hydrophilicity of the modified gold electrode. Figure 4 shows the change of WCA in different modification steps. As can be seen in Figure 4A, the WCA of the bare electrode is 95.3° since the gold electrode is hydrophobic. When Apt1 was immobilized on the gold electrode, the WCA decreased to 92.3° (Fig. 4B), which was caused by the hydrophilic groups on Apt1. After blocking the unbound sites on the surface with MCH, the WCA did not change much, only dropping to 91.2° (Fig. 4C), which is due to the presence of both hydrophobic and hydrophilic groups on MCH. Due to the presence of hydrophilic amino and carboxyl groups in the protein, WCA decreased to 86.8° when CEA specifically recognized Apt1 (Fig. 4D). Likewise, WCA was significantly reduced to 76.5° after Apt2-PEI was attached to the electrode due to the presence of a large number of amino groups on PEI (Fig. 4E). After the BMP was attached to the electrode via an amide bond, the WCA was reduced to 72.6° due to the action of the amide bond and halogen (Fig. 4F). Finally, the polymer chains with FMMA were grafted onto the electrode, and the contact angle of the electrode dropped to 71.8° due to the hydrophilic methacrylate in the polymer (Fig. 4G). The above results prove that the present invention is feasible for detecting CEA.
实施例5:检测条件优化Example 5: Optimization of detection conditions
为了使试剂盒的性能达到最佳,对电极构建过程中的重要条件进行优化,包括BMP反应时间、eATRP时间等,以提高试剂盒的分析性能。In order to maximize the performance of the kit, important conditions in the electrode construction process were optimized, including BMP reaction time, eATRP time, etc., to improve the analytical performance of the kit.
(1)BMP反应时间(1) BMP reaction time
BMP作为eATRP的引发剂,连接到电极上的量直接影响聚合反应的发生。随着反应时间的延长,越来越多的引发剂附着到电极上,为聚合提供更多的反应位点,电流强度逐渐增大。图5A为BMP时间与电流强度的关系图,在前25min内,电流随反应时间增长,25min后电流强度几乎保持不变,这是因为反应达到了平衡。因此,选择25min作为最佳反应时长。As the initiator of eATRP, the amount of BMP attached to the electrode directly affects the occurrence of the polymerization reaction. With the prolongation of the reaction time, more and more initiators were attached to the electrodes, providing more reaction sites for polymerization, and the current intensity gradually increased. Figure 5A shows the relationship between BMP time and current intensity. In the first 25 min, the current increased with the reaction time, and the current intensity remained almost unchanged after 25 min, because the reaction reached equilibrium. Therefore, 25 min was chosen as the optimal reaction time.
(2)eATRP反应时间(2) eATRP reaction time
同样的,在聚合反应中,FMMA的聚合量也受到eATRP反应时间的影响。由图5B可知,随着聚合时间的延长,电流强度逐渐增大,在40min左右达到最大值。这是因为大量的FMMA被接枝到电极上,电极表面的位阻逐渐增大,从而限制了聚合反应的进行。因此,eATRP的最佳反应时间为40min。Similarly, in the polymerization reaction, the polymerization amount of FMMA is also affected by the reaction time of eATRP. It can be seen from Fig. 5B that with the extension of the polymerization time, the current intensity gradually increases and reaches the maximum value at about 40 min. This is because a large amount of FMMA was grafted onto the electrode, and the steric hindrance on the electrode surface gradually increased, thus limiting the progress of the polymerization reaction. Therefore, the optimal reaction time of eATRP was 40 min.
实施例6:分析性能Example 6: Analyzing Performance
在最佳条件下,用构建的电极在1M LiClO4溶液中采用SWV法检测不同浓度的CEA,从而研究该电极的检测范围和检测限。由图6可知,在10-3~102ng·mL-1范围内,CEA浓度与电流强度呈现良好的线性关系,线性回归方程为:I(μA)=1.1165lg CCEA+4.8054(R2=0.998),检测限为:70.17fg·mL-1(S/N=3)。Under optimal conditions, the constructed electrode was used to detect different concentrations of CEA in 1M LiClO4 solution by SWV method to study the detection range and detection limit of this electrode. It can be seen from Figure 6 that in the range of 10 -3 to 10 2 ng·mL -1 , the CEA concentration and the current intensity have a good linear relationship. The linear regression equation is: I(μA)=1.1165lg C CEA +4.8054(R 2 =0.998), the detection limit was: 70.17 fg·mL -1 (S/N=3).
与其它几种方法相比,本发明所提出的方法检测CEA,检测范围更大、检测限更低,这表明本发明试剂盒在癌症的早期检测中具有潜在的应用价值(下表)。Compared with several other methods, the method proposed in the present invention detects CEA with a larger detection range and lower detection limit, which indicates that the kit of the present invention has potential application value in the early detection of cancer (table below).
实施例7:试剂盒的特异性、抗干扰能力、稳定性和重现性Example 7: Specificity, anti-interference ability, stability and reproducibility of the kit
为了验证本发明对于不同蛋白质的特异性,以确保其检测性能,在最佳条件下,比较了该试剂盒对10ng·mL-1CEA、细胞角蛋白19片段(CYFRA 21-1,CY)、牛血清白蛋白(BSA)、心肌肌钙蛋白(CTnI)以及100mU·mL-1碱性磷酸酶(ALP)的选择性。由图7A可以看出,CEA与其它酶和蛋白质产生的信号存在明显差异,CY、CTnI、ALP的电流强度分别只占CEA的8.96%、7.26%、7.15%。这是由于Apt与CEA之间具有良好特异性,但是可能存在部分碱基与BSA识别,导致BSA的信号相对较高,达到CEA的28.65%,但其与CEA电流强度也存在明显差异。In order to verify the specificity of the present invention for different proteins to ensure its detection performance, under optimal conditions, the kits were compared for 10 ng·mL -1 CEA, cytokeratin 19 fragment (CYFRA 21-1, CY), Selectivity of bovine serum albumin (BSA), cardiac troponin (CTnI) and 100mU·mL -1 alkaline phosphatase (ALP). It can be seen from Figure 7A that there are significant differences in the signals produced by CEA and other enzymes and proteins. The current intensities of CY, CTnI, and ALP only account for 8.96%, 7.26%, and 7.15% of CEA, respectively. This is due to the good specificity between Apt and CEA, but there may be some bases that recognize BSA, resulting in a relatively high signal of BSA, reaching 28.65% of CEA, but there is also a significant difference between its current intensity and CEA.
为了研究本发明在人血清中的抗干扰能力,分别检测不同浓度CEA在10%人血清中的信号强度,并将人血清样品中CEA的信号与PBS缓冲液中的信号进行对比。从图7B中可以看出:10ng·mL-1、100pg·mL-1、5pg·mL-1的CEA在人血清中测得的信号分别比在PBS缓冲液中测得的小了3.63%、1.12%、8.37%。说明本发明在检测CEA时具有一定的抗干扰能力,具有临床应用潜力。In order to study the anti-interference ability of the present invention in human serum, the signal intensities of different concentrations of CEA in 10% human serum were respectively detected, and the signal of CEA in human serum samples was compared with the signal in PBS buffer. It can be seen from Figure 7B that the signals of 10ng·mL -1 , 100pg·mL -1 , and 5pg·mL -1 of CEA measured in human serum are 3.63% smaller than those measured in PBS buffer, respectively. 1.12%, 8.37%. It shows that the invention has certain anti-interference ability when detecting CEA, and has clinical application potential.
为了评价本发明的稳定性,比较了新构建的电极和储存一段时间后的电极的信号强度。在相同条件下制备了两组修饰电极,一组构建完成后立即检测信号强度,另一组将制备好的电极在4℃中保存14天后进行检测。结果显示,存储两周后测得的信号强度是新制备电极的93.8%,说明该电极稳定性良好。To evaluate the stability of the present invention, the signal intensities of the newly constructed electrodes and the electrodes after storage for a period of time were compared. Two groups of modified electrodes were prepared under the same conditions. One group was constructed to detect the signal intensity immediately, and the other group was stored at 4°C for 14 days for detection. The results show that the signal intensity measured after two weeks of storage is 93.8% of that of the newly prepared electrode, indicating that the electrode has good stability.
除此之外,还在相同实验条件下探讨了本发明重现性。实验结果表明,组内和组间相对标准偏差分别为:1.78%和3.09%。说明本发明具有良好的重现性。In addition to this, the reproducibility of the present invention was also investigated under the same experimental conditions. The experimental results showed that the relative standard deviations within and between groups were 1.78% and 3.09%, respectively. It shows that the present invention has good reproducibility.
实施例8:实际应用价值Example 8: Practical application value
最后,为了验证该试剂盒的实际应用价值,对获得的5个不同的临床血清样品进行检测。实验结果如下表所示,测得的结果与临床测得的数据相对误差都小于5%,表明该试剂盒可以对实际临床样品进行检测,具有一定的临床应用价值。Finally, in order to verify the practical application value of the kit, 5 different clinical serum samples obtained were tested. The experimental results are shown in the following table. The relative error between the measured results and the clinically measured data is less than 5%, indicating that the kit can detect actual clinical samples and has certain clinical application value.
序列表sequence listing
<110> 河南中医药大学<110> Henan University of Traditional Chinese Medicine
<120> 基于eATRP信号放大策略的CEA电化学检测试剂盒及检测方法<120> CEA electrochemical detection kit and detection method based on eATRP signal amplification strategy
<160> 2<160> 2
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 22<211> 22
<212> DNA<212> DNA
<213> 人工序列()<213> artificial sequence()
<400> 1<400> 1
shchatacca gcttattcaa tt 22shchatacca gcttattcaa tt 22
<210> 2<210> 2
<211> 19<211> 19
<212> DNA<212> DNA
<213> 人工序列()<213> artificial sequence()
<400> 2<400> 2
agggggtgaa gggataccc 19agggggtgaa gggataccc 19
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210359045.2A CN114778839A (en) | 2022-04-06 | 2022-04-06 | CEA electrochemical detection kit based on eATRP signal amplification strategy and detection method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210359045.2A CN114778839A (en) | 2022-04-06 | 2022-04-06 | CEA electrochemical detection kit based on eATRP signal amplification strategy and detection method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114778839A true CN114778839A (en) | 2022-07-22 |
Family
ID=82428077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210359045.2A Pending CN114778839A (en) | 2022-04-06 | 2022-04-06 | CEA electrochemical detection kit based on eATRP signal amplification strategy and detection method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114778839A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114410735A (en) * | 2022-01-25 | 2022-04-29 | 河南中医药大学 | Electrochemical kit for detecting alkaline phosphatase by using ATRP signal amplification strategy with amifostine as substrate and using method |
CN115728489A (en) * | 2022-08-17 | 2023-03-03 | 河南中医药大学 | A fluorescent detection kit for exosomes based on in situ triggering ARGET ATRP signal amplification and its application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110208348A (en) * | 2019-07-02 | 2019-09-06 | 河南中医药大学 | A kind of lung cancer detection box of the atom transition free radical polymerization reaction mediated as initiator by electrochemistry using Nafion |
-
2022
- 2022-04-06 CN CN202210359045.2A patent/CN114778839A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110208348A (en) * | 2019-07-02 | 2019-09-06 | 河南中医药大学 | A kind of lung cancer detection box of the atom transition free radical polymerization reaction mediated as initiator by electrochemistry using Nafion |
Non-Patent Citations (3)
Title |
---|
BASHIR ADEL等: "Utilization of rGO-PEI-supported AgNPs for sensitive recognition of deltamethrin in human plasma samples: A new platform for the biomedical analysis of pesticides in human biofluids", J MOL RECOGNIT, 31 December 2021 (2021-12-31), pages 1 - 16 * |
LIYING ZHAO等: "Dual signal amplification by polysaccharide and eATRP for ultrasensitive detection of CYFRA 21–1 DNA", BIOSENSORS AND BIOELECTRONICS, 31 December 2019 (2019-12-31), pages 1 - 27 * |
ZHENLI QIU等: "Near-Infrared-to-Ultraviolet Light-Mediated Photoelectrochemical Aptasensing Platform for Cancer Biomarker Based on Core−Shell NaYF4:Yb, Tm@TiO2 Upconversion Microrods",,", ANAL. CHEM., 24 November 2017 (2017-11-24), pages 1021 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114410735A (en) * | 2022-01-25 | 2022-04-29 | 河南中医药大学 | Electrochemical kit for detecting alkaline phosphatase by using ATRP signal amplification strategy with amifostine as substrate and using method |
CN114410735B (en) * | 2022-01-25 | 2023-10-27 | 河南中医药大学 | Electrochemical kit and usage method for detecting alkaline phosphatase using ATRP signal amplification strategy using amifostine as substrate |
CN115728489A (en) * | 2022-08-17 | 2023-03-03 | 河南中医药大学 | A fluorescent detection kit for exosomes based on in situ triggering ARGET ATRP signal amplification and its application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110208348B (en) | Lung cancer detection kit using Nafion as initiator through electrochemical-mediated atom transfer radical polymerization reaction | |
CN111175507B (en) | A kit for early diagnosis of lung cancer based on signal amplification of ring-opening polymerization induced by hydroxyl-functionalized graphene oxide | |
CN114778839A (en) | CEA electrochemical detection kit based on eATRP signal amplification strategy and detection method | |
CN102706939A (en) | Electrochemical immunosensor for directly detecting IL-6 (interleukin-6) antigen and application thereof | |
CN113252745B (en) | A kind of biosensor and its preparation method, application, application method | |
Cui et al. | An antifouling electrochemical biosensor based on a protein imprinted hydrogel for human immunoglobulin G recognition in complex biological media | |
Aydın et al. | Ultrasensitive determination of cadherin-like protein 22 with a label-free electrochemical immunosensor using brush type poly (thiophene-g-glycidylmethacrylate) modified disposable ITO electrode | |
CN115201302B (en) | An electrochemical sensor and its preparation method and application | |
Zhou et al. | Dual-signal amplified electrochemical biosensor based on eATRP and PEI for early detection of lung cancer | |
Gao et al. | Electrochemical biosensor for highly sensitive detection of cTnI based on a dual signal amplification strategy of ARGET ATRP and ROP | |
Li et al. | A high-performance PEDOT: PSS platform electrochemical biosensor for the determination of HER2 based on carboxyl-functionalized MWCNTs and ARGET ATRP | |
Zhou et al. | Dual signal amplified electrochemical aptasensor based on PEI-functionalized GO and ROP for highly sensitive detection of cTnI | |
Peng et al. | Hybridization chain reaction-enhanced electrochemically mediated ATRP coupling high-efficient magnetic separation for electrochemical aptasensing of cardiac troponin I | |
CN118655208A (en) | HER2 electrochemical detection kit based on TDN and MXene-Au coupled with ARGET ATRP | |
CN117969625B (en) | Photoelectrochemical aptamer sensor based on polypeptide-nucleic acid conjugate and its preparation method and application | |
Hu et al. | Rose bengal-mediated photoinduced atom transfer radical polymerization for high sensitivity detection of target DNA | |
CN106950270A (en) | A kind of CEA Concentration Testings probe and preparation method and application, and CEA Concentration Testing biology sensors | |
CN104316705B (en) | Preparation method and application of hybridization indicator 5, 7-dinitro-2-sulfo-acridone | |
CN112763553B (en) | Electrochemical detection method for protein based on molecular imprinting technology | |
CN114720697B (en) | Highly sensitive cTnI detection kit and its application based on ROP signal amplification strategy induced by FFAPO | |
TWI796010B (en) | Matrix metalloproteinase-1 peptide rubbing conductive polymer and its application | |
CN114410735A (en) | Electrochemical kit for detecting alkaline phosphatase by using ATRP signal amplification strategy with amifostine as substrate and using method | |
Cui et al. | A novel electrochemical biosensor based on WO 3@ AuNPs and HBP@ BIBB macromolecule-triggered ATRP for DR1 detection | |
CN116297731A (en) | HER2 electrochemical detection kit based on functionalized nano material and ARGET ATRP and application thereof | |
CN116643053A (en) | Highly sensitive cTnI detection kit based on ARGET ATRP and ROP dual polymerization cascade amplification and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |